Ambroxol, a known active-site-directed PC [19, 43, 69, 99] currently being evaluated in a multi-center Phase 3A clinical trial for patients with PD and known GBA1 status (NCT05778617), was identified as a highly active compound in the unbiased primary screen. This evidence concerns the gene GBA1 and Parkinson disease.